Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
about
How do kinases contribute to tonicity-dependent regulation of the transcription factor NFAT5?The GSK-3 family as therapeutic target for myocardial diseasesGSK-3 as potential target for therapeutic intervention in cancerInduction of Human iPSC-Derived Cardiomyocyte Proliferation Revealed by Combinatorial Screening in High Density Microbioreactor Arrays.Mitochondrial adenine nucleotide transport and cardioprotectionRemote ischemic preconditioning differentially attenuates post-ischemic cardiac arrhythmia in streptozotocin-induced diabetic versus nondiabetic rats.A screen for regulators of survival of motor neuron protein levelsAMP activated protein kinase is indispensable for myocardial adaptation to caloric restriction in mice.Chronic high-fat diet-induced obesity decreased survival and increased hypertrophy of rats with experimental eccentric hypertrophy from chronic aortic regurgitation.The diabetic heart: too sweet for its own good?Acute inhibition of GSK causes mitochondrial remodeling.Aldose reductase modulates cardiac glycogen synthase kinase-3β phosphorylation during ischemia-reperfusion.Cardiac-specific knockout of ET(A) receptor mitigates low ambient temperature-induced cardiac hypertrophy and contractile dysfunctionInhibitory phosphorylation of GSK-3β by AKT, PKA, and PI3K contributes to high NaCl-induced activation of the transcription factor NFAT5 (TonEBP/OREBP)Kcne2 deletion attenuates acute post-ischaemia/reperfusion myocardial infarctionGlycogen synthase kinase-3 regulation of urinary concentrating abilityGSK-3β controls NF-kappaB activity via IKKγ/NEMO.Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseasesProtein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials.Fine-Tuning of the RIG-I-Like Receptor/Interferon Regulatory Factor 3-Dependent Antiviral Innate Immune Response by the Glycogen Synthase Kinase 3/β-Catenin PathwayPharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.GSK-3α is a central regulator of age-related pathologies in mice.Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy.Cyclin D2 is a critical mediator of exercise-induced cardiac hypertrophy.Nuclear GSK-3β segregation in desmoid-type fibromatosis.GSK-3 Inhibitors: Anti-Diabetic Treatment Associated with Cardiac Risk? : Editorial to: "The Impact of Chronic Glycogen Synthase Kinase-3 Inhibition on Remodeling of Normal and Pre-Diabetic Rat Hearts." by Barbara Huisamen et al.The Impact of Chronic Glycogen Synthase Kinase-3 Inhibition on Remodeling of Normal and Pre-Diabetic Rat Hearts.
P2860
Q26770757-E4F7F708-42CC-425D-A778-039385741014Q26861134-B34AD111-D99E-4723-BE13-96BB1855CD96Q27013811-0C146C99-3EDF-4BD1-B40C-56D74CA4E131Q27320900-3577A689-E99A-47D9-81DB-7F8F1DF03B72Q28740277-C7CEFCE1-01F9-42B3-85C4-987CC4509155Q33608846-8FEB71D9-7F61-4D4B-B9A9-B1DD1341BC09Q33936321-6688750B-4E83-4517-AD82-B22361AFECEFQ34635436-94CF62E8-C64D-45C7-8F4C-C2CA9965BAA4Q35272139-6B8E73C0-51F0-49C6-9C00-CE9CC15AAC4EQ35810679-D3CF71F2-BF2E-46F3-84B2-82C0D92D8A4EQ36042607-9DE6E801-AEA0-4E25-8E10-F2029D82A004Q36176141-31C53474-A1C1-4695-A5EA-5B5EFB2BF960Q36727926-0FD2B306-6867-4226-AC86-B388EB029126Q36764258-237A3DF9-83A2-4069-9B50-7CFF015E16BEQ36812653-7ACD751A-7ABB-43CC-A070-A9E89690DA4CQ37139392-D668548D-A225-48D5-BD98-596A7ABD5721Q37483862-2DC71BC9-C4BD-431C-9D86-0F2E462F95F0Q37640802-7F7467EB-4041-43DA-8AB1-FF85032FC401Q38272835-20CB486A-CB00-405B-A8EB-5348F4890F88Q38670275-13B3A68E-46EA-471A-A34B-6CEBF7CF0D17Q38861095-EA678968-0BC2-4304-A21A-4BE7F223532EQ39008696-89B130A5-E154-464E-B6FF-A17E69B43D83Q39498781-7E1FDD20-B7E2-4DC1-9926-DCAC76F9E106Q40579189-C3E99C76-6684-487E-9BC3-ECE385F08E24Q47812655-2935ADC4-BAD1-4C53-AE60-39F665E81D92Q51045139-85E89509-6B0E-4597-A079-54453A6114FEQ51699473-D08EF5A4-FC16-40E4-8857-95EB8B2283EDQ52869439-F521767D-521F-43F7-B78B-F094C2B85B76
P2860
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@ast
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@en
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@nl
type
label
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@ast
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@en
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@nl
prefLabel
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@ast
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@en
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@nl
P2860
P1476
Targeting GSK-3 family members in the heart: a very sharp double-edged sword.
@en
P2093
Mia Maamari
P2860
P304
P356
10.1016/J.YJMCC.2010.11.020
P577
2010-12-13T00:00:00Z